Stéphane Depil (S Depil)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 15

Top Venues

Cellular & molecular immunology

Science advances

Nature reviews. Drug discovery

Université Lille 2 Droit et Santé (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Université Lille 2 Droit et Santé

France

PHD

Publications

Audrey Page, Nicolas Chuvin, Jenny Valladeau-Guilemond, Stéphane Depil
Development of NK cell-based cancer immunotherapies through receptor engineering. Cellular & molecular immunology 21 (4) (2024)
Audrey Page, Nicolas Chuvin, Jenny Valladeau-Guilemond, Stéphane Depil
Development of NK cell-based cancer immunotherapies through receptor engineering. Cellular & molecular immunology (2024)
Audrey Page, Nicolas Chuvin, Jenny Valladeau-Guilemond, Stéphane Depil
Development of NK cell-based cancer immunotherapies through receptor engineering. Cellular & molecular immunology 21 (4) (2024)
Audrey Page, Nicolas Chuvin, Jenny Valladeau-Guilemond, Stéphane Depil
Development of NK cell-based cancer immunotherapies through receptor engineering. Cellular & molecular immunology 21 (4) (2024)
Audrey Page, Nicolas Chuvin, Jenny Valladeau-Guilemond, Stéphane Depil
Development of NK cell-based cancer immunotherapies through receptor engineering. Cellular & molecular immunology (2024)
Audrey Page, Nicolas Chuvin, Jenny Valladeau-Guilemond, Stéphane Depil
Development of NK cell-based cancer immunotherapies through receptor engineering. Cellular & molecular immunology 21 (4) (2024)
Audrey Page, Nicolas Chuvin, Jenny Valladeau-Guilemond, Stéphane Depil
Development of NK cell-based cancer immunotherapies through receptor engineering. Cellular & molecular immunology 21 (4) (2024)
Audrey Page, Nicolas Chuvin, Jenny Valladeau-Guilemond, Stéphane Depil
Development of NK cell-based cancer immunotherapies through receptor engineering. Cellular & molecular immunology 21 (4) (2024)
Audrey Page, Nicolas Chuvin, Jenny Valladeau-Guilemond, Stéphane Depil
Development of NK cell-based cancer immunotherapies through receptor engineering. Cellular & molecular immunology 21 (4) (2024)
Estelle Baulu, Célia Gardet, Nicolas Chuvin, Stéphane Depil
TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Science advances 9 (7) (2023)
Estelle Baulu, Célia Gardet, Nicolas Chuvin, Stéphane Depil
TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Science advances 9 (7) (2023)
Estelle Baulu, Célia Gardet, Nicolas Chuvin, Stéphane Depil
TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Science advances 9 (7) (2023)
Estelle Baulu, Célia Gardet, Nicolas Chuvin, Stéphane Depil
TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Science advances 9 (7) (2023)
Paola Bonaventura, Vincent Alcazer, Virginie Mutez, Laurie Tonon, Juliette Martin, Nicolas Chuvin, Emilie Michel, Rasha E Boulos, Yann Estornes, Jenny Valladeau-Guilemond, Alain Viari, Qing Wang, Christophe Caux, Stéphane Depil
Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy. Science advances 8 (4) (2022)
Stéphane Depil, P Duchateau, S A Grupp, G Mufti, Laurent Poirot
'Off-the-shelf' allogeneic CAR T cells: development and challenges. Nature reviews. Drug discovery 19 (3) (2020)

Stéphane Depil.css-eqlu8i{font-size:small;padding-left:4px;} (S Depil)

Publication Activity (10 Years)

Top Topics

Top Venues

Stéphane Depil (S Depil)